That drug could have hope for individuals who do not respond to the current drugs because they carry viruses which are resistant to the other drugs such as the protease inhibitors. It's actually being tested in combination therapies. The results are encouraging. The T20 does appear to have a significant impact on virus activity in patients. The drug is not ideal because of the structure of the drug.
Patients have to be implanted with a little pump which is loaded with the drug.
This pump is implanted under the skin and delivers a measured dose of the drug at a steady rate. The drug cannot be administered by swallowing a capsule. It can't get into the body that way. The pump has to be removed periodically to renew the drug. It's usually inserted in the chest or under the arm so that it's not too visible.